Article Text

Download PDFPDF
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
  1. Ashish B Rajput1,
  2. Melinda A Miller3,
  3. Alessandro De Luca3,
  4. Niki Boyd3,
  5. Sam Leung1,
  6. Antonio Hurtado-Coll2,
  7. Ladan Fazli2,
  8. Edward C Jones2,
  9. Jodie B Palmer2,
  10. Martin E Gleave2,
  11. Michael E Cox2,
  12. David G Huntsman1
  1. 1
    Genetic Pathology Evaluation Centre, Vancouver General Hospital, British Columbia Cancer Agency, and the University of British Columbia, Vancouver, British Columbia, Canada
  2. 2
    The Prostate Centre at Vancouver General Hospital, Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada
  3. 3
    Center for Translational and Applied Genomics, Provincial Health Services Authority & British Columbia Cancer Agency, Vancouver, British Columbia, Canada
  1. Dr David G Huntsman, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada; dhuntsma{at}


Background: Recent reports indicate that prostate cancers (CaP) frequently over-express the potential oncogenes, ERG or ETV1. Many cases have chromosomal rearrangements leading to the fusion of the 5′ end of the androgen-regulated serine protease TMPRSS2 (21q22.2) to the 3′ end of either ERG (21q22.3) or ETV1 (7p21.3). The consequence of these rearrangements is aberrant androgen receptor-driven expression of the potential oncogenes, ETV1 or ERG.

Aim: To determine the frequency of rearrangements involving TMPRSS2, ERG, or ETV1 genes in CaP of varying Gleason grades through fluorescence in situ hybridisation (FISH) on CaP tissue microarrays (TMAs).

Methods: Two independent assays, a TMPRSS2 break-apart assay and a three-colour gene fusion FISH assay were applied to TMAs. FISH positive cases were confirmed by reverse transcriptase (RT) PCR and DNA sequence analysis.

Results: A total of 106/196 (54.1%) cases were analysed by FISH. None of the five benign prostatic hyperplasia cases analysed exhibited these gene rearrangements. TMPRSS2:ERG fusion was found more frequently in moderate to poorly differentiated tumours (35/86, 40.7%) than in well differentiated tumours (1/15, 6.7%, p = 0.017). TMPRSS2:ETV1 gene fusions were not detected in any of the cases tested. TMPRSS2:ERG fusion product was verified by RT-PCR followed by DNA sequencing in 7/7 randomly selected positive cases analysed.

Conclusion: This study indicates that TMPRSS2:ERG gene rearrangements in CaP may be used as a diagnostic tool to identify prognostically relevant sub-classifications of these cancers.

  • gene fusion
  • prostate cancer
  • FISH

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: This work was supported in part by the Canadian Institutes of Health Research Strategic Training Program (Grant STP-53912). The Genetic Pathology Evaluation Centre is supported by an educational grant from Sanofi-Aventis, Canada. D Huntsman and M Cox are Michael Smith Health Foundation for Research Scholars. A De Luca is a recipient of the Michael Smith Health Foundation for Research post-doctoral award and J Palmer is supported in part by the British Columbia Foundation for Prostate Cancer Research.

  • Competing interests: None declared.

  • Abbreviations:
    prostate cancer
    fluorescence in situ hybridisation
    prostate specific antigen
    tissue microarray

Linked Articles